Worldwide Pelvic Inflammatory Disease Therapeutics Industry to 2025 - Rise in Healthcare Awareness Presents Opportunities - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pelvic Inflammatory Disease Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The pelvic inflammatory disease therapeutics (PIDT) market studied was anticipated to grow with a CAGR of nearly 5.6% during the forecast period. The major factors attributing to the growth of the market are rise in urinary tract infections, sexually transmitted diseases (STDs), and severe complications associated with PID such as increased rate of Polycystic ovary syndrome (PCOS) cases, and infertility.

According to the study report published by the National Center for Biotechnology in 2018, the prevalence of lower genital tract infections, such as bacterial vaginosis, vulvovaginitis etc., is higher in women with infertility which is projected to be continued in future which is likely to fuel the demand for efficient treatment driving the global PID market throughout the forecast period.

Key Market Trends

Tetracyclines Segment is Expected to Hold the Major Market Share in the Pelvic Inflammatory Disease Therapeutics Market

The tetracycline drugs are expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment and recommendations of cephalosporin along with doxycycline, a tetra cycline drug by the CDC as first line treatment of pelvic inflammatory disease. Also, rapid advancements in new product development with reduced side effects coupled with the availability of a wide range of marketed products are expected to fuel the market. Furthermore, the disadvantages such as increased resistance of bacterium to other drug classes like fluoroquinolone antibiotics for the CDC doesn't recommend regular use in the U.S. is also expected increase the sales of the products in the segment during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global PIDT drugs market throughout the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, polycystic ovary syndrome, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, etc., due to change in lifestyles and a rise in stress among women in the United States which registers the highest revenue in the region. For instance, according to the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age and 1 in 8 women with a history of PID experience difficulties getting pregnant in the United States fueling the market.

Also, the availability of advanced healthcare infrastructure, increase in government expenditure for the women healthcare, rise in geriatric women population along with early product launches with enhanced quality in the region are expected to contribute its outstanding share in the growth of global market revenue over the forecast period.

Companies Mentioned

• Pfizer Inc
• Perrigo Company plc
• Galderma Laboratories LP
• Mayne Pharma
• Bristol-Myers Squibb Company
• Mylan N.V.
• Genzyme Corporation
• Teligent Inc
• F. Hoffmann-La Roche Ltd
• Sanofi S.A
  

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of STD, and Infectious Diseases across the Globe

4.2.2 Rise in Healthcare Awareness along with the Increasing Ageing Female Population

4.3 Market Restraints

4.3.1 Stringent Regulatory Framework that Delays the Approval of Products

4.3.2 Expensive Patented Products and Severe Complications Associated with the Medication

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 Drug Class

5.1.1 Macrolides

5.1.2 Tetracycline

5.1.3 Beta-lactam

5.1.4 Nitroimidazoles

5.1.5 Others

5.2 Route of Administration

5.2.1 Oral

5.2.2 Parenteral

5.2.3 Others

5.3 Distribution Channel

5.3.1 Hospital Pharmacies

5.3.2 Retail Pharmacies

5.3.3 Online Pharmacies

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle-East and Africa

5.4.5 South America

6 COMPETITIVE LANDSCAPE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/35dtz8